Find appropriate medical studies or publications
Budget: $30 – $250 USD
Purpose: To find recent study results and field reports on treatment strategies/therapies, that may be effective for concurrent two active blood cancers, CLL of B-cell type and multiple myeloma.
Medical history: as an incidental finding, CLL of the B-cell type was diagnosed in 2007 in a then 63-year-old man, who was observed only analytically every six months until 2019. In 2019, the CLL became active, the presence of an 11q deletion was detected and it was treated by chemotherapy with bendamustine and rituximab for six months in the second half of the year. Already in the spring of 2021, the CLL became active again in yet another more aggressive form and was treated with the BTK inhibitor "ibrutinib" from 1.6.2021. Due to atrial fibrillation and atrial damage, therapy was switched to the BTK inhibitor "acalabrutinib" from September. Due to increasing significant back pain from November on, a lumbar spine MRI on 12/29/2021 revealed that several vertebral bodies were significantly deformed, the lumbar spine 2 had to be described as fractured, and osseous metastases were present on the spine. By bone marrow biopsy, a "multiple myeloma (plasmacytoma) with restriction of the lambda light chain" was found to be the cause of this spinal decomposition, which was not seen in the regular previous oncological blood tests. With the start of myeloma therapy (three weeks of 1x daily Lenalindomide (Revlimid 15mg), 1x weeklyDexamethasone TAD 20mg, 1x weekly Daratumumab 500ml- infusion currently pausing due to poor tolerability) the leukemia therapy with Acalabrutinib, was reduced from 2x1 per day to 1x1/day.
Medical history: as an incidental finding, CLL of the B-cell type was diagnosed in 2007 in a then 63-year-old man, who was observed only analytically every six months until 2019. In 2019, the CLL became active, the presence of an 11q deletion was detected and it was treated by chemotherapy with bendamustine and rituximab for six months in the second half of the year. Already in the spring of 2021, the CLL became active again in yet another more aggressive form and was treated with the BTK inhibitor "ibrutinib" from 1.6.2021. Due to atrial fibrillation and atrial damage, therapy was switched to the BTK inhibitor "acalabrutinib" from September. Due to increasing significant back pain from November on, a lumbar spine MRI on 12/29/2021 revealed that several vertebral bodies were significantly deformed, the lumbar spine 2 had to be described as fractured, and osseous metastases were present on the spine. By bone marrow biopsy, a "multiple myeloma (plasmacytoma) with restriction of the lambda light chain" was found to be the cause of this spinal decomposition, which was not seen in the regular previous oncological blood tests. With the start of myeloma therapy (three weeks of 1x daily Lenalindomide (Revlimid 15mg), 1x weeklyDexamethasone TAD 20mg, 1x weekly Daratumumab 500ml- infusion currently pausing due to poor tolerability) the leukemia therapy with Acalabrutinib, was reduced from 2x1 per day to 1x1/day.